Phase 3 study of new drug for dry eye in the United States receives positive top-line data

On February 24, Essex Biotech and Mitotech jointly announced the positive top-line data of the VISTA-2 study-a randomized, double-blind, placebo-controlled, multicenter SkQ1 treatment for dry eye (DED) in the United States3 Phase clinical trials.

Public information shows that SkQ1 acts on mitochondria at the cellular level through an innovative mechanism to achieve the goal of treating dry eye.

Dry eye is a chronic ophthalmological disease in which the patient suffers from eye discomfort and inflammation due to damage to the tear film of the eye.

VISTA-2 is a randomized, double-blind, placebo-controlled, multi-center clinical trial, which includes two treatment groups, each receiving SkQ1 eye drops and placebo twice a day.

One of the key secondary endpoints (baseline changes in central fluorescein staining after only 28 days of treatment) was preset in the study.

According to the press release, the data results of the above secondary endpoints provide clear guidance for Mitotech's next round of key clinical studies targeting new drug applications, which will replace the combined clinical endpoints of VISTA-2 (day 56 conjunctiva).

Mr.